The protective effect of SARS-CoV-2 antibodies in Scottish healthcare workers by Abo-Leyah, Hani et al.
                                                                    
University of Dundee
The protective effect of SARS-CoV-2 antibodies in Scottish healthcare workers









Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Abo-Leyah, H., Gallant, S., Cassidy, D., Giam, Y. H., Killick, J., Marshall, B., Hay, G., Snowdon, C., Hothersall,
E. J., Pembridge, T., Strachan, R., Gallant, N., Parcell, B. J., George, J., Furrie, E., & Chalmers, J. D. (2021).
The protective effect of SARS-CoV-2 antibodies in Scottish healthcare workers. ERJ Open Research, 7(2),
[00080-2021]. https://doi.org/10.1183/23120541.00080-2021
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 22. Jun. 2021
The protective effect of SARS-CoV-2
antibodies in Scottish healthcare workers
Hani Abo-Leyah1, Stephanie Gallant1, Diane Cassidy1, Yan Hui Giam1,
Justin Killick2, Beth Marshall2, Gordon Hay2, Caroline Snowdon3,
Eleanor J. Hothersall3, Thomas Pembridge1, Rachel Strachan1,
Natalie Gallant1, Benjamin J. Parcell4, Jacob George1, Elizabeth Furrie2,5 and
James D. Chalmers1,5
Affiliations: 1Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, Dundee, UK.
2Dept of Immunology, NHS Tayside, Ninewells Hospital and Medical School, Dundee, UK. 3Dept of Public
Health, NHS Tayside, Ninewells Hospital and Medical School, Dundee, UK. 4Dept of Microbiology, NHS
Tayside, Ninewells Hospital and Medical School, Dundee, UK. 5These authors contributed equally.
Correspondence: James D. Chalmers, University of Dundee, Ninewells Hospital and Medical School, DD1 9SY,
UK. E-mail: j.chalmers@dundee.ac.uk
ABSTRACT
Background: Healthcare workers (HCWs) are believed to be at increased risk of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection. It is not known to what extent the natural production of
antibodies to SARS-CoV-2 is protective against re-infection.
Methods: A prospective observational study of HCWs in Scotland (UK) from May to September 2020 was
performed. The Siemens SARS-CoV-2 total antibody assay was used to establish seroprevalence in this
cohort. Controls, matched for age and sex to the general local population, were studied for comparison.
New infections (up to 2 December 2020) post antibody testing were recorded to determine whether the
presence of SARS-CoV-2 antibodies protects against re-infection.
Results: A total of 2063 health and social care workers were recruited for this study. At enrolment, 300
HCWs had a positive antibody test (14.5%). 11 out of 231 control sera tested positive (4.8%). HCWs
therefore had an increased likelihood of a positive test (OR 3.4, 95% CI 1.85–6.16; p<0.0001). Dentists
were most likely to test positive. 97.3% of patients who had previously tested positive for SARS-CoV-2 by
reverse transcriptase (RT)-PCR had positive antibodies. 18.7% had an asymptomatic infection. There were
38 new infections with SARS-CoV-2 in HCWs who were previously antibody negative, and one
symptomatic RT-PCR-positive re-infection. The presence of antibodies was therefore associated with an
85% reduced risk of re-infection with SARS-CoV-2 (hazard ratio 0.15, 95% CI 0.06–0.35; p=0.026).
Conclusion: HCWs were three times more likely to test positive for SARS-CoV-2 than the general
population. Almost all infected individuals developed an antibody response, which was 85% effective in
protecting against re-infection with SARS-CoV-2.
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Healthcare workers (HCWs) are known to be at increased risk of symptomatic infection with severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) [1, 2]. HCWs accounted for 21% of SARS cases during
the outbreak in 2002 [3] and high rates of symptomatic infections have been reported across Europe
during the present pandemic, including in the UK [4]. Measures taken to mitigate this increased risk
include adequate personal protective equipment (PPE) [5], infection prevention and control (IPC)
procedures within healthcare environments and staff testing. Across the UK, for healthcare and other key
workers with symptoms, testing has been widely available since April 2020 [6].
A key challenge in containing the spread of SARS-CoV-2 has been the potential for asymptomatic or
atypical infection [7]. Even in the case of symptomatic individuals, reverse transcriptase (RT)-PCR on
nasopharyngeal, oropharyngeal or combined upper airway swabs has a reported sensitivity of 70–90% and
consequently will underestimate the number of infected individuals [8]. Therefore, the extent of infections
in HCWs in different parts of the world remain largely unknown.
Serological testing can be used to determine the incidence and prevalence of SARS-CoV-2 infection [9].
Identifying the extent of HCW infections and the proportion of undetected infections is important to
inform IPC measures during future waves of the pandemic.
An antibody response is expected after infection with SARS-CoV-2 but the rate of antibody development
has not been extensively reported. Little is known about the protective effect of natural immunity and no
studies have been published that demonstrate how protective natural antibodies are against re-infection
with SARS-CoV-2.
In this study, we investigated the seroprevalence of SARS-CoV-2 antibodies in a large population of
Scottish HCWs. We also investigated whether the presence of antibodies protects against re-infection with
the virus.
Methods
We conducted a prospective observational study recruiting HCWs employed within the National Health
Service in Tayside (NHS Tayside). NHS Tayside is an NHS board in the East of Scotland (UK) that is
responsible for delivering healthcare for over 400000 people and employs around 14000 staff.
Healthcare staff were invited to participate in the study via advertisements, including e-mail newsletters
and posted adverts on the staff intranet page. Recruitment took place during a single study visit at
Ninewells Hospital (Dundee, UK), which is the health board’s largest teaching hospital. Recruitment took
place between 28 May 2020 and 2 September 2020. Electronic results were followed up until 2 December
2020, to record new laboratory-confirmed infections. All participants gave written informed consent to
participate. The study was approved by the West of Scotland Research Ethics committee, approval number
20/WS/0078.
The inclusion criteria were: employment as a health or social care worker, and age >16 years. Participants
were excluded if they had any contraindication to venepuncture, symptoms consistent with current
SARS-CoV-2 infection at the time of enrolment, or had tested positive for SARS-CoV-2 in the preceding
14 days.
At the study visit, participants completed a questionnaire on demographics, previous symptoms,
employment role, hours of work, contact with patients with coronavirus disease 2019 (COVID-19)
infection and whether they had previously tested positive for SARS-CoV-2. Blood samples were taken for
measurement of SARS-CoV-2 antibodies in serum.
SARS-CoV-2 antibody detection
The Siemens SARS-CoV-2 total antibody assay was used in this study. This is a one stop bridging
chemiluminescent immunoassay method that detects antibodies against the receptor-binding domain of
the SARS-CoV-2 spike (S1) protein. The assay is performed on the Siemens Atellica 1300 platform.
Validation of this assay was approved by the NHS Scotland national laboratories programme quality group
and was then further validated against other commercial antibody platforms in a previous study and found
to have 95–100% sensitivity, while titres remained constant beyond 81 days following a positive PCR test
result [10].
Population control subjects
A random selection of blood samples taken at NHS Tayside General Practice Surgeries were tested,
covering the same time period as the HCW study cohort. Samples were age and sex matched to the
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Scottish population demographics to provide a representative sample of the local population, to determine
the background prevalence of SARS-CoV-2. Serum samples were run on the same Siemens analyser.
Follow-up
All individuals in Scotland have a unique identifier number (community health index) that links to their
healthcare records. Using these identifiers, participants’ antibody data were linked to results of
symptomatic testing for SARS-CoV-2 at regional and national laboratories. Immediate testing for HCWs
displaying symptoms is available in the study region, ensuring all symptomatic SARS-CoV-2 infections
would be captured during follow-up until 2 December 2020.
Statistical analysis
Data were analysed using IBM SPSS v25 and GraphPad Prism 8.1.2. Chi-squared and Fisher’s tests were
used as appropriate to compare proportions between groups. Logistic regression was used to derive the
odds ratio values for the reported symptom analysis. Kaplan–Meier survival analysis with follow-up from
date of antibody testing until 2 December 2020 was used with groups compared using the log-rank
(Mantel–Cox) test. A p-value <0.05 was considered statistically significant for all analyses.
Results
A total of 2063 health and social care workers were recruited for this study. The participants were
predominantly female (81.7%) and 95.5% were white. The median age of participants was 46 years.
Table 1 presents the demographic characteristics of the study participants and their healthcare roles.
Seroprevalence of SARS-CoV-2 antibodies
In our study, 300 HCWs had a positive antibody test directed against SARS-CoV-2 spike protein. This
represents a seroprevalence of 14.5%. 11 out of 231 control sera tested positive (4.8%), which was
consistent with the broader Scottish surveillance data reported by Health Protection Scotland (214 positive
tests out of 4751; 4.5%). Compared to both sets of population controls, HCWs had 3.6 times greater odds
of a positive test compared to local controls (OR 3.4, 95% CI 1.85–6.16; p<0.0001) and compared to
Scotland-wide controls (OR 3.6, 95% CI 2.99–4.32; p<0.001).
Table 1 shows the seroprevalence rate among subgroups in our study characterised by demographic, job
role and area of work. Male sex was more frequently associated with detected antibodies (18.5% versus
13.7%; p=0.02). Some job roles were significantly associated with a higher rate of SARS-CoV-2 antibody
detection. HCWs in dentistry were the most frequently associated with detected antibodies (26%), followed
by healthcare assistants (23.3%) and hospital porters (22.2%) (p<0.0001 when comparing across groups).
Figure 1 displays the rates of antibody prevalence among the HCWs, by profession.
Healthcare staff who worked in areas of the hospital that treated suspected or confirmed cases of
COVID-19 were more frequently associated with detected antibodies (17.4% versus 13.5%; p=0.03). Staff
who worked in critical care and the intensive care unit were not more frequently associated with detected
antibodies (16% versus 14.4%; p=0.61).
Prior positive test results and symptomatic infections
797 study participants had a SARS-CoV-2 RT-PCR swab prior to enrolment into the study and therefore
prior to antibody measurement. 111 of these were positive for SARS-CoV-2 prior to enrolment. 97.3%
(108 out of 111) of participants with positive RT-PCR had detectable antibodies. 10.9% of participants
with a negative PCR test prior to enrolment had detectable antibody levels. In those who never had an
RT-PCR test, 8.9% had detectable antibodies. Figure 2 displays the proportions of PCR-positive and
PCR-negative participants with detected antibodies.
45.4% (n=936) of the HCWs recruited believed they had had COVID-19 but only 25.1% (n=235) of these
HCWs had detectable antibodies. Conversely, 18.7% (n=56) of those who had antibodies detected did not
believe they ever had had COVID-19 and were completely asymptomatic.
5.1% (n=56) of asymptomatic participants had detectable antibodies compared to 25.6% (n=243) of
symptomatic recruits who had detectable antibodies. When compared with the general population,
individuals who did not have a symptomatic illness during the period of the study did not have an
increased frequency of SARS-CoV-2 antibodies (OR 1.20, 95% CI 0.30–4.83; p=0.26).
Anosmia was the self-reported symptom that was most likely to correspond with detected antibodies (OR
12.3, 95% CI 9.3–16.3; p<0.001) but was only reported in 5.8% of HCWs at any time (table 2). A
combination of cough, fever and anosmia was only reported at a frequency of 2.6% but when present
was associated with a 10-fold increase in odds of detectable antibody (OR 9.7, 95% CI 6.4–14.7; p<0.001).
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The absence of any cough, fever and anosmia was associated with an 82% chance of not having detectable
antibodies (OR 0.2, 95% CI 0.14–0.24; p<0.001).
Infection rate and antibody protection during second wave of infections
In the 3 months following the end of the recruitment period, there were 39 new symptomatic infections
with SARS-CoV-2. 38 of these 39 infections were in HCWs who did not have prior antibodies to
SARS-CoV-2.
There was only one re-infection (1 out of 300; 0.33%) with SARS-CoV-2. This re-infection was in a
symptomatic HCW who tested positive by RT-PCR 76 days after having detectable antibodies in their
serum.
From the first recorded PCR-positive infection in this cohort to the end of the follow-up period was
261 days and from the first positive antibody test to the end of the follow-up period was 188 days. Figure 3
shows an analysis of time from antibody testing to development of PCR-confirmed symptomatic
SARS-CoV-2 infection. This demonstrates that having antibodies to SARS-CoV-2 at baseline is highly
protective against re-infection (hazard ratio 0.15, 95% CI 0.06–0.35; p=0.026) over a follow-up period of
up to 6 months.
TABLE 1 Demographic characteristics and seroprevalence of study participants, including
roles and areas of work
Characteristic n (% of total) Antibody positive n Seroprevalence % p-value
Sex 0.02*
Male 378 (18.3) 70 18.5
Female 1685 (81.7) 230 13.7
Age years 0.5
18–30 290 (14.1) 46 15.9
31–40 403 (19.5) 60 14.9
41–50 536 (26.0) 76 14.2
51–60 637 (30.9) 97 15.2
>60 196 (9.5) 21 10.7
Ethnicity 0.86
White European 1964 (95.5) 285 14.5
Other White 16 (0.8) 2 12.5
South Asian 36 (1.7) 8 22.2
Chinese 10 (0.5) 1 10.0
Black 8 (0.4) 2 25.0
Arab 5 (0.2) 1 20.0
Traveller 2 (0.1) 0 0.0
Other ethnic 16 (0.8) 1 6.3
Role <0.0001*
Doctor 237 (11.5) 50 21.1
Nurse 601 (29.2) 80 13.3
AHP 239 (11.6) 25 10.5
Pharmacy staff 69 (3.4) 9 13.0
HCA 172 (8.4) 40 23.3
Student 25 (1.2) 4 16.0
Domestic 84 (4.1) 11 13.1
Admin 403 (19.6) 49 21.1
Porter 27 (1.3) 6 22.2
Other# 151 (7.3) 13 8.6
Dentistry 50 (2.4) 13 26.0
Area 0.03*
COVID-19 552 (26.8) 96 17.4
Non-COVID-19 1511 (73.2) 204 13.5
Critical care 0.61
Yes 131 (6.3) 21 16.0
No 1931 (93.7) 279 14.4
AHP: allied health professional; HCA: healthcare assistant; Admin: administrative staff. #: other roles
included lab technician, health scientist, maintenance, laundry, medical physics, other technician, patient
transport, chaplaincy, volunteers. Chi-squared and Fisher’s exact tests were used to determine statistical
significance. *: p<0.05, statistically significant.
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Discussion
In this observational study of health and social care workers, the SARS-CoV-2 seroprevalence rate was
14.5%. Importantly, the presence of antibodies was associated with clear protection against subsequent
infection. This is important for our future understanding of risk for HCWs and the general population.
At the time of writing, Health Protection Scotland is leading a surveillance study for COVID-19 in
Scotland on behalf of the Scottish Government [11]. Present data from this study demonstrate a
comparative seroprevalence of 4.5%. Our data therefore suggest that health and social care workers are >3
times more likely to be positive for spike protein antibodies and thus are likely to have been infected with
SARS-CoV-2.
Other HCW seroprevalence studies conducted in the rest of the UK have also reported higher
seropositivity when compared to the general population, with seroprevalence rates of 24.4% [12], 25.4%
[13] and 10.7% [14].
Our study was notable for the inclusion of dentistry staff, who had the highest seroprevalence rate at 26%.
This was well above the average seroprevalence rate of 14.5% among our HCWs, although this higher rate
should be interpreted with some caution given the lower number of dentistry staff enrolled (table 1).
Dentistry staff are expected to be a higher risk group, given their focus of work is more likely to be aerosol
generating and with close exposure to potentially infected mucosal surfaces [15]. Healthcare assistants,
including such staff at nursing homes, had the second highest prevalence at 23%. The caring roles of these
workers necessitate close patient contact and their increased risk was also reported in a recent Swedish
study [16].
In other published HCW studies [12], domestic or housekeeping staff had the highest seroprevalence of
antibodies. This was not evident in our study, where domestic staff had a below average seroprevalence
rate of 13.1%. Other groups who had a seroprevalence rate above average were hospital porters and
doctors. Doctors and porters are typically exposed to multiple patients in different working areas.
FIGURE 2 Proportion of antibody
detection according to PCR status.
97.3% of PCR-positive individuals











FIGURE 1 Percentage prevalence of
SARS-CoV-2 antibody among
different healthcare worker roles.
Staff working in dentistry had the
highest prevalence. AHP: allied
health professional; Admin: admini-
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By comparison, nurses typically care for up to six patients in a defined area during their working day. The
variability in work location in a particular time period could be a factor in the increased infection rate we
observed.
In our study, HCWs who worked in COVID-19 areas of the hospital had a slightly higher seroprevalence
than those workers who did not. This finding is consistent with other studies, including HCW studies
conducted in major urban areas where the community burden of COVID-19 was a significant source of
exposure [17]. Working in COVID-19 areas of the hospital is one way to define high-risk exposure.
Nevertheless, the majority of SARS-CoV-2 infections detected in this study occurred in staff who were not
working directly with COVID-19 patients, and this group still had a significantly higher prevalence of
SARS-CoV-2 antibodies than the general population. While a seroprevalence study cannot establish the
source of infection, this strongly suggests transmission between healthcare staff within non-clinical
environments, since many staff roles that did not involve direct contact with patients were still associated
with an increased rate of antibody positivity. Therefore, while much media attention has focused on the
importance of PPE for front-line staff, these data emphasise the importance of IPC measures in
non-clinical areas within healthcare environments such as hospitals. The relative success of measures to
protect high-risk front-line staff is illustrated by the low rate of antibody detection in critical care staff. All
staff working in critical care areas wore PPE in accordance with Health Protection Scotland guidance on
working in aerosol-generating procedures [18]. We found no significantly increased risk of infection for
these staff. In the recently published study from Birmingham, UK [12], staff in intensive care had a
significantly lower risk of seropositivity.
We asked our study participants to report if they thought they had had COVID-19 and list the symptoms
they experienced. We describe that only one in four participants who thought they had contracted
FIGURE 3 Survival curve showing
protective effect of pre-existing
antibodies to developing new
SARS-CoV-2 infections. Those who
had previously detected antibodies






























TABLE 2 Frequency of reported symptoms and odds ratios of each symptom corresponding to
detectable antibodies against SARS-CoV-2
Symptoms Frequency % OR (95% CI) p-value
Fatigue 15.4 4.5 (3.458–5.912) 0.0001
Headache 12.3 3.6 (2.809–4.653) 0.0001
Cough 11.8 2.1 (1.619–2.67) 0.0001
Myalgia 11.7 3.8 (2.931–4.856) 0.0001
Fever 10.0 2.5 (1.74–2.901) 0.0001
Sore throat 9.8 1.4 (1.092–1.86) 0.009
Dyspnoea 9.2 2.4 (1.825–3.076) 0.0001
Runny nose 5.9 1.2 (0.835–1.61) 0.378
Anosmia 5.8 12.3 (9.306–16.348) 0.0001
Other 5.0 3.5 (2.615–4.705) 0.001
Diarrhoea 3.1 2.5 (1.773–3.66) 0.0001
CFA 2.6 9.7 (6.433–14.738) 0.0001
Absence of CFA 13.1 0.2 (0.136–0.239) 0.001
CFA: combination of cough, fever and anosmia.
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COVID-19 demonstrated serological evidence of infection. The heightened suspicion of infection is
justified among HCWs, but perceived infection does not correlate well with actual infection. This has some
potentially important implications when considering the issue of chronic symptoms in individuals who
believe they have had COVID-19 infection [19]. However, we demonstrated in this study that certain
symptoms are significantly more predictive of infection with SARS-CoV-2. Anosmia represented 12-fold
increased odds of having serological evidence of infection. This particular symptom was also shown to be
strongly predictive in similar analysis performed in other European studies [16, 20].
Our study demonstrates that approximately one-fifth (18.7%) of seropositive HCWs were completely
asymptomatic. This is consistent with studies that only recruited asymptomatic HCWs [12] and indicates
that a significant proportion of the healthcare workforce will attend work without knowing that they may
potentially transmit the infection to their colleagues.
After the end of the recruitment period, we followed our study participants for up to 6 months from
antibody positivity and up to 10 months from first PCR-confirmed SARS-CoV-2 infection. Winter 2020
coincided with the second wave of SARS-CoV-2 infections in Scotland and we had 39 new infections
among our HCWs during this period. One of these infections (0.33% of the total study group) was a
symptomatic re-infection in an HCW who had previously developed an antibody response from a
previous infection. To our knowledge, this is the first reported case of laboratory-confirmed re-infection
after the development and confirmed presence of natural antibodies.
97.4% of new infections were in HCWs who did not have previous antibodies. In our study, the presence
of a natural antibody response was therefore 85% protective against re-infection with SARS-CoV-2 over a
period of 6 months (May to December 2020).
Our results on antibody protection fit within the range of efficacy of vaccine-mediated immunity reported
in the recently published SARS-CoV-2 vaccine trials [21, 22]. These results may have implications for the
roll-out of vaccine programmes, since HCWs are often prioritised, but our results suggest HCWs with
prior infection may be at low risk of future infection and may therefore be considered a lower priority.
This study has potential limitations, including potentially that individuals more likely to believe they have
had a SARS-CoV-2-like illness would be more likely to volunteer for such a study. Nevertheless, we were
successful in enrolling participants who had never experienced a symptomatic infection and demonstrate
an increased seroprevalence even among this group. We enrolled patients up to September 2020 and
therefore potentially up to 4–5 months post infection. This raises the possibility of antibodies waning over
time [23]. This seems unlikely, as a prior study found no evidence of waning of the Siemens assay over
4 months [10], while a similar total spike protein antibody assay showed no waning over time in a study
from Iceland [24]. Other studies have reported increased infection rates in the Black, Asian and minority
ethnic populations [25–27]. We were unable to investigate this as NHS Tayside has a workforce that is
97% white. The patient population was representative of NHS Scotland staff. In 2019, the median age of
staff employed across NHS Scotland was 46 years, and 77.4% of NHS Scotland employees were female. 9%
were doctors, 0.4% dental staff, 42.6% nursing staff, 8.4% allied health professionals and 18.1%
administrative staff. Our sample included 11.5% doctors, 29.2% nurses, 11.6% allied health professionals
and 19.6% administrative staff. Our median age was 46 years and 81.7% of our cohort were female.
Conclusion
Our study suggests that HCWs are at increased risk of infection with SARS-CoV-2 compared with the
general population. Our study suggests a differential risk among hospital staff and a high proportion of
undetected symptomatic and asymptomatic infections. This will help to inform targeted IPC strategies
during future epidemics. We report a single re-infection in an HCW who had developed natural
antibodies and we estimate the natural antibody response is 85% protective against re-infection.
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